Rallybio Corporation and Avenzo Therapeutics conducted a merger call on June 1, 2026, to discuss their proposed combination.
The call opened with remarks from Steve Uden, co-founder, president, chief executive officer and director at Rallybio. He noted that the discussion would include forward-looking statements on the expected timing, completion and outcomes of the transaction, along with plans for the combined company such as clinical development and cash runway milestones.
Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.
Von KI berichtet
BioMarin Pharmaceutical Inc. conducted its first-quarter 2026 earnings conference call on May 4, 2026. Company executives, including CEO Alexander Hardy, presented financial results and updates. The call included forward-looking statements and non-GAAP measures.
Ceva, Inc. conducted its first quarter 2026 earnings conference call on May 11, 2026. Executives reviewed business performance and highlighted key financial measures during the event.
Von KI berichtet
Cytek Biosciences released its financial results for the first quarter of 2026 on May 7. The company then hosted an earnings conference call the same day at 4:30 PM EDT.